Clinical Study
Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes
Table 2
Treatment characteristics for reirradiation.
| | Patient characteristic | | Percent |
| | Recurrent/new disease site | | | | Anterior tongue | 2 | 10% | | Base of tongue | 4 | 20% | | Buccal Mucosa | 2 | 10% | | Retromolar trigone | 1 | 5% | | Maxilla | 4 | 20% | | Floor of mouth | 1 | 5% | | Nasal cavity | 2 | 10% | | Larynx | 2 | 10% | | Hypopharynx | 1 | 5% | | Alvelous | 1 | 5% | | Stage | | | | II | 5 | 25% | | III | 9 | 45% | | IV | 6 | 30% | | Radiotherapy technique | | | | IMRT | 7 | 35% | | SIB VMAT | 10 | 50% | | 3DCRT | 1 | 5% | | Conventional 2D radiotherapy | 2 | 10% | | Interval from previous RT | months | | | (Mean ± SD) | (Range 16–309 months) | | | RT dose (mean ± SD) | Gy | | | | (Range 30–60 Gy) | | | Reirradiated volume (mean ± SD) | cc | | | | (Range 17.91–781.92 cc) | | | BED3 (mean ± SD Gy) | | |
|
|
IMRT, intensity modulated radiotherapy; SIB VMAT, simultaneous integrated boost volumetric modulated arc radiotherapy; 3DCRT, 3-dimensional conformal radiotherapy; SD, standard deviation; BED3, biologically effective dose for α/β value 3.
|
